Drug Profile
Research programme: stroke therapeutics - Astellas Pharma/Quark Pharmaceuticals
Alternative Names: FR-210575; Stroke research programme - Astellas Pharma/Quark PharmaceuticalsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Astellas Pharma; Quark Biotech
- Developer Astellas Pharma; SBI Biotech
- Class Cinnamates; Small molecules; Triazines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Stroke in USA
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 11 Aug 2003 Quark and Fujisawa have extended their research collaboration